Sino Biopharmaceutical Limited provided earnings guidance for the six months ended 30 June 2021. The group's profit attributable to the owners of the parent for the six months ended 30 June 2021 is expected to increase by over 500% as compared to the same period last year (profit attributable to the owners of the parent (restated) for the same period last year was RMB 1,240.61 million).